Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02233894

Enrollment

526

Registered

2014-09-09

Start date

2001-02-28

Completion date

Unknown

Last updated

2014-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Interventions

DRUGAtrovent® - inhalets

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease * Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion

Exclusion criteria

* Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler

Design outcomes

Primary

Measure	Time frame
Change in overall severity of the clinical picture	3 months

Secondary

Measure	Time frame
Assessment of efficacy by investigator on a 4-point scale	after 3 months
Assessment of efficacy by patient on a 4-point scale	after 3 months
Number of patients with adverse drug reactions	3 months
Assessment of tolerability by investigator on a 4-point scale	after 3 months
Assessment of tolerability by patient on a 4-point scale	after 3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026